Stock Track | ImmunityBio Surges on Promising Cancer Treatment Plans

Stock Track10-29

Shares of ImmunityBio, Inc. (IBRX) soared over 5% in pre-market trading on Monday, as investors reacted positively to the company's plans to address gaps in cancer treatments.

According to reports, ImmunityBio aims to bridge the divide between immunotherapy and more traditional cancer treatments. The biotech firm is working on a novel approach that combines immunotherapy with chemotherapy and other targeted therapies, potentially offering a more comprehensive solution for cancer patients.

The company's unique strategy has generated significant interest, with the stock price surging over 77% in recent days. Investors seem optimistic about the potential of ImmunityBio's innovative approach to tackle cancer more effectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128282064?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 19:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128282064","market":"us","top_or_hot":-1,"title":"Stock Track | ImmunityBio Surges on Promising Cancer Treatment Plans","media":"Stock Track","content":"<p>Shares of ImmunityBio, Inc. (IBRX) soared over 5% in pre-market trading on Monday, as investors reacted positively to the company's plans to address gaps in cancer treatments.</p>\n\n<p>According to reports, ImmunityBio aims to bridge the divide between immunotherapy and more traditional cancer treatments. The biotech firm is working on a novel approach that combines immunotherapy with chemotherapy and other targeted therapies, potentially offering a more comprehensive solution for cancer patients.</p>\n\n<p>The company's unique strategy has generated significant interest, with the stock price surging over 77% in recent days. Investors seem optimistic about the potential of ImmunityBio's innovative approach to tackle cancer more effectively.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | ImmunityBio Surges on Promising Cancer Treatment Plans</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | ImmunityBio Surges on Promising Cancer Treatment Plans\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-29 19:36 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of ImmunityBio, Inc. (IBRX) soared over 5% in pre-market trading on Monday, as investors reacted positively to the company's plans to address gaps in cancer treatments.\nAccording to reports, ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1128282064","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128282064","pubTimestamp":1730201775,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of ImmunityBio, Inc.  soared over 5% in pre-market trading on Monday, as investors reacted positively to the company's plans to address gaps in cancer treatments.According to reports, ImmunityBio aims to bridge the divide between immunotherapy and more traditional cancer treatments. The biotech firm is working on a novel approach that combines immunotherapy with chemotherapy and other targeted therapies, potentially offering a more comprehensive solution for cancer patients.The company's ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"股票追踪ImmunityBio因有前途的癌症治疗计划而飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"Shares of ImmunityBio, Inc. (IBRX) soared over 5% in pre-market trading on Monday, as investors reacted positively to the company's plans to address gaps in cancer treatments.\nAccording to reports, ImmunityBio aims to bridge the divide between immunotherapy and more traditional cancer treatments. The biotech firm is working on a novel approach that combines immunotherapy with chemotherapy and other targeted therapies, potentially offering a more comprehensive solution for cancer patients.\nThe company's unique strategy has generated significant interest, with the stock price surging over 77% in recent days. Investors seem optimistic about the potential of ImmunityBio's innovative approach to tackle cancer more effectively.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128282064"}